Business Context and Reporting Period
Company: Anavex Life Sciences Corp. (AVXL)
Filing Type: Form 8-K (Current Report)
Date of Report: June 7, 2019
Event: Entry into a Material Definitive Agreement (2019 Purchase Agreement) with Lincoln Park Capital Fund, LLC (LPC).
Key Financial Metrics and Capital Structure
This filing details a capital raising facility rather than operational financial results. Key terms include:
- Total Commitment: Up to $50,000,000 in common stock sales over a 36-month period.
- Regular Purchase Limits: Up to 200,000 shares per business day (capped at $2,000,000 per purchase), with potential for mutual agreement to increase to 1,000,000 shares.
- Share Issuance Cap: Limited to 10,076,680 shares (19.99% of outstanding shares) unless shareholder approval is obtained or specific price thresholds are met.
- Beneficial Ownership Limit: LPC cannot acquire more than 4.99% of total outstanding shares at any single point in time.
- Commitment Fee: 324,383 shares issued immediately, plus up to 162,191 shares pro rata upon full commitment utilization.
- Use of Proceeds: General corporate purposes, working capital, capital expenditures, and funding clinical/preclinical development.
Note: The filing text does not provide current revenue, profit, cash flow, margins, or debt figures.
Material Changes and Agreements
The 2019 Purchase Agreement succeeds the 2015 Purchase Agreement with LPC. While the 2015 agreement remains active until terminated, the new agreement provides a fresh 36-month window for sales. The agreement prohibits the Company from entering into "Variable Rate Transactions" (e.g., floating conversion rate securities) during the term, excluding standard "At-the-Market" offerings. LPC has covenanted not to engage in short selling or hedging of the Company's stock.
Outlook, Risks, and Management Commentary
Management Intent: Proceeds are designated to fund the pipeline of clinical and preclinical candidates.
Flexibility: The Company retains the right to terminate the agreement at any time without cost.
Risks/Contingencies: Sales are subject to customary conditions and the 4.99% beneficial ownership cap for LPC. The agreement relies on the Company's effective shelf registration statement (Form S-3); if this becomes unavailable, a new registration statement must be filed.
Investor Verification Checklist
- Verify the current number of outstanding shares to confirm the 19.99% issuance cap (10,076,680 shares).
- Review the full text of the 2019 Purchase Agreement (Exhibit 10.1) for specific pricing formulas and termination clauses.
- Confirm the status of the 2015 Purchase Agreement and whether it has been formally terminated.
- Monitor the Company's cash burn rate to assess the necessity of utilizing the full $50 million commitment.
- Check for any subsequent filings regarding the actual execution of "Regular Purchases" or "Accelerated Purchases."